{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:25:14Z","timestamp":1793816714626,"version":"4.6.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jhep.2024.07.019","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T06:46:23Z","timestamp":1722408383000},"page":"211-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial"],"prefix":"10.1016","volume":"82","author":[{"given":"Fahong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongliang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengdi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.07.019_bib1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2024.07.019_bib2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, European association for the study of the L. EASL 2017 clinical Practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.07.019_bib4","first-page":"22","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)","volume":"35","year":"2019","journal-title":"J\u00a0Clin Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.07.019_bib7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","author":"Seto","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.07.019_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/liv.14654","article-title":"Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues","volume":"41","author":"Manolakopoulos","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.07.019_bib9","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1002\/hep.31616","article-title":"HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy","volume":"73","author":"Mak","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.07.019_bib10","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1136\/gutjnl-2019-320015","article-title":"Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study","volume":"69","author":"Kim","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.07.019_bib11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","article-title":"Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B","volume":"222","author":"Fan","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2024.07.019_bib12","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","article-title":"Associations of HBV genotype B vs C infection with relapse after cessation of entecavir or tenofovir therapy","volume":"18","author":"Chiu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-019-09991-y","article-title":"Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy","volume":"14","author":"Chen","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.07.019_bib14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.07.019_bib15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1053\/j.gastro.2021.12.240","article-title":"Withdrawal of nucleos(t)ide analogues in the treatment of chronic hepatitis B: a cornelian choice","volume":"162","author":"Pol","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.07.019_bib16","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/jvh.13729","article-title":"Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy","volume":"29","author":"Papatheodoridi","year":"2022","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2024.07.019_bib17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.07.019_bib18","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","article-title":"A\u00a0multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B","volume":"78","author":"van Bommel","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.16968","article-title":"Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels","volume":"56","author":"Hall","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.07.019_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.07.019_bib21","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.29213","article-title":"A\u00a0potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.07.019_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2024.07.019_bib23","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/liv.14330","article-title":"The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B","volume":"40","author":"Wong","year":"2020","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.jhep.2024.07.019_bib25","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2024.07.019_bib26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2024.07.019_bib27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.07.019_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3350\/cmh.2022.0172","article-title":"Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B","volume":"29","author":"Mak","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib29","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/jmv.24715","article-title":"Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: a 10-year follow-up study","volume":"89","author":"Kang","year":"2017","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jhep.2024.07.019_bib31","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/infdis\/jix025","article-title":"Off-treatment hepatitis B virus (HBV) DNA levels and the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B: a prospective stop study","volume":"215","author":"Cao","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2024.07.019_bib33","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.07.019_bib34","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.07.019_bib35","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.07.019_bib36","first-page":"25","article-title":"HBsAg loss with peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study","volume":"6","author":"Hu","year":"2018","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","article-title":"Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients","volume":"65","author":"Boyd","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib38","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jhep.2024.07.019_bib39","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2024.07.019_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba6322","article-title":"Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection","volume":"13","author":"Nishio","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2024.07.019_bib41","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","article-title":"Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B","volume":"69","author":"Rinker","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib42","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI92812","article-title":"Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation","volume":"128","author":"Rivino","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2024.07.019_bib43","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/infdis\/jiy097","article-title":"Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss","volume":"217","author":"Zimmer","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2024.07.019_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005788","article-title":"Interferon alpha induces sustained changes in NK cell responsiveness to hepatitis B viral load suppression in\u00a0vivo","volume":"12","author":"Gill","year":"2016","journal-title":"Plos Pathog"},{"key":"10.1016\/j.jhep.2024.07.019_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1067362","article-title":"Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN alpha-2a therapy","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2024.07.019_bib46","first-page":"592","article-title":"Differential response of HBV envelope-specific CD4\u00a0+ T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy","volume":"78","author":"Li","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.07.019_bib47","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1111\/liv.14897","article-title":"Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers","volume":"41","author":"Wu","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.07.019_bib48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jvh.13792","article-title":"Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: a real-world analysis","volume":"30","author":"Zhang","year":"2023","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2024.07.019_bib49","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib50","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.16538","article-title":"Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment","volume":"54","author":"Xia","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.07.019_bib51","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/apt.16850","article-title":"Model to predict on-treatment restoration of functional HBV-specific CD8(+) cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B","volume":"55","author":"Pena-Asensio","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.07.019_bib52","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2024.07.019_bib53","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1097\/MCG.0000000000001376","article-title":"Serum HBV RNA dynamic and drug withdrawal predictor value in patients with chronic HBV infection on long-term nucleos(t)ide analogue (NA) therapy","volume":"54","author":"Liu","year":"2020","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2024.07.019_bib54","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/jvh.13195","article-title":"Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"26","author":"Limothai","year":"2019","journal-title":"J\u00a0Viral Hepat"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824024267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824024267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T22:50:02Z","timestamp":1736981402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824024267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0168827824024267"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.07.019","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PegIFN alpha-2a reduces relapse in HBeAg-negative patients after nucleo(s)tide analogue cessation: A randomized-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}